Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | DEC 01 | ChemPort single article sales feature unavailable |
| NEWS | 3 | JAN 06 | The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS | 4 | JAN 07 | WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |
| NEWS | 5 | FEB 02 | Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE |
| NEWS | 6 | FEB 02 | GENBANK enhanced with SET PLURALS and SET SPELLING |
| NEWS | 7 | FEB 06 | Patent sequence location (PSL) data added to USGENE |
| NEWS | 8 | FEB 10 | COMPENDEX reloaded and enhanced |
| NEWS | 9 | FEB 11 | WTEXTILES reloaded and enhanced |
| NEWS | 10 | FEB 19 | New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art |
| NEWS | 11 | FEB 19 | Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01 |
| NEWS | 12 | FEB 23 | Several formats for image display and print options discontinued in USPATFULL and USPAT2 |
| NEWS | 13 | FEB 23 | MEDLINE now offers more precise author group fields and 2009 MeSH terms |
| NEWS | 14 | FEB 23 | TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms |
| NEWS | 15 | FEB 23 | Three million new patent records blast AEROSPACE into STN patent clusters |
| NEWS | 16 | FEB 25 | USGENE enhanced with patent family and legal status display data from INPADOCDB |
| NEWS | 17 | MAR 06 | INPADOCDB and INPAFAMDB enhanced with new display formats |
| NEWS | 18 | MAR 11 | EPFULL backfile enhanced with additional full-text applications and grants |
| NEWS | 19 | MAR 11 | ESBIOBASE reloaded and enhanced |
| NEWS | 20 | MAR 20 | CAS databases on STN enhanced with new super role for nanomaterial substances |
| NEWS | 21 | MAR 23 | CA/CAplus enhanced with more than 250,000 patent equivalents from China |
| NEWS | 22 | MAR 30 | IMSPATENTS reloaded and enhanced |
| NEWS | 23 | APR 03 | CAS coverage of exemplified prophetic substances enhanced |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

| | |
|---|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:02:02 ON 06 APR 2009

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.22 | 0.22 |

FILE 'REGISTRY' ENTERED AT 13:02:11 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10564139s1.str



chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
6-7 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19
15-16 16-17 16-20 17-18 17-22 18-19 20-21 21-22
exact/norm bonds :
6-7 7-8 7-12 8-9 9-10 10-11 10-13 11-12 16-20 17-22 20-21 21-22
exact bonds :
13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:02:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          671 TO     1569
PROJECTED ANSWERS:              33 TO      447

L2           12 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:02:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1306 TO ITERATE

100.0% PROCESSED     1306 ITERATIONS                              301 ANSWERS
SEARCH TIME: 00.00.01

L3          301 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     185.88     186.10

FILE 'CAPLUS' ENTERED AT 13:02:33 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=>  s l3 and nasal and (aqueous or spray or powder)
          482 L3
        26074 NASAL
            1 NASALS
        26075 NASAL
                (NASAL OR NASALS)
       210171 AQUEOUS
            1 AQUEOUSES
       210172 AQUEOUS
                (AQUEOUS OR AQUEOUSES)
      1148784 AQ
          206 AQS
      1148912 AQ
```

```
                (AQ OR AQS)
        1203178 AQUEOUS
                (AQUEOUS OR AQ)
         155126 SPRAY
          35610 SPRAYS
         175425 SPRAY
                (SPRAY OR SPRAYS)
         627288 POWDER
         219593 POWDERS
         725519 POWDER
                (POWDER OR POWDERS)
         202446 POWD
            255 POWDS
         202573 POWD
                (POWD OR POWDS)
         854343 POWDER
                (POWDER OR POWD)
L4            1 L3 AND NASAL AND (AQUEOUS OR SPRAY OR POWDER)

=> d ibib abs hitstr 1

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:56829  CAPLUS
DOCUMENT NUMBER:          142:141273
TITLE:                    Pharmaceutical composition for the nasal
                          administration of piribedil
INVENTOR(S):              Rolland, Herve; Wuthrich, Patrick
PATENT ASSIGNEE(S):       Les Laboratoires Servier, Fr.; Servier Lab
SOURCE:                   Fr. Demande, 9 pp.
                          CODEN: FRXXBL
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     FR 2857594            A1    20050121    FR 2003-8712            20030717
     FR 2857594            B1    20050916
     AU 2004258714         A1    20050203    AU 2004-258714          20040716
     CA 2532631            A1    20050203    CA 2004-2532631         20040716
     WO 2005009442         A1    20050203    WO 2004-FR1867          20040716
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1653963            A1    20060510    EP 2004-767691          20040716
     EP 1653963            B1    20061227
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1819828            A     20060816    CN 2004-80019749        20040716
     BR 2004012681         A     20061003    BR 2004-12681           20040716
     AT 349213             T     20070115    AT 2004-767691          20040716
     JP 2007516947         T     20070628    JP 2006-519966          20040716
     ES 2279435            T3    20070816    ES 2004-767691          20040716
```

| | | | | | |
|---|---|---|---|---|---|
| NZ 544460 | A | 20080430 | NZ 2004-544460 | | 20040716 |
| IN 2006DN00118 | A | 20070824 | IN 2006-DN118 | | 20060106 |
| US 20060204449 | A1 | 20060914 | US 2006-564139 | | 20060110 |
| MX 2006000641 | A | 20060330 | MX 2006-641 | | 20060117 |
| KR 2006031689 | A | 20060412 | KR 2006-701141 | | 20060117 |
| KR 807480 | B1 | 20080225 | | | |
| NO 2006000743 | A | 20060216 | NO 2006-743 | | 20060216 |
| PRIORITY APPLN. INFO.: | | | FR 2003-8712 | A | 20030717 |
| | | | WO 2004-FR1867 | W | 20040716 |

AB The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin) 750, and NaCl 68 mg, and water qs to 10 mL.

IT 3605-01-4, Piribedil
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for nasal administration of piribedil)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l3 and nasal
          482 L3
        26074 NASAL
            1 NASALS
        26075 NASAL
                (NASAL OR NASALS)
L5          7 L3 AND NASAL

=> d ibib abs hitstr 1-7
```

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2009:233290 CAPLUS |
| DOCUMENT NUMBER: | 150:252678 |
| TITLE: | Combinations containing MPO inhibitors against neuroinflammatory disorders |
| INVENTOR(S): | Aahlberg, Gabrielle; Eriksson, Haakan |
| PATENT ASSIGNEE(S): | Astrazeneca AB, Swed. |
| SOURCE: | PCT Int. Appl., 41pp.<br>CODEN: PIXXD2 |
| DOCUMENT TYPE: | Patent |
| LANGUAGE: | English |
| FAMILY ACC. NUM. COUNT: | 1 |

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2009025617 | A1 | 20090226 | WO 2008-SE50949 | 20080822 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, | | | | |

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090053176 A1 20090226 US 2008-195505 20080821
PRIORITY APPLN. INFO.: US 2007-957524P P 20070823

AB The present invention related to a combination of (a) a compound which is a MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a compound or a pharmaceutically acceptable salt thereof, which is used in the treatment and/or prevention of PD or Multiple Sclerosis. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating Neuroinflammatory and Neurodegenerative Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).

IT 3605-01-4, Piribedil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations containing MPO inhibitors against neuroinflammatory disorders)

RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1359892 CAPLUS
DOCUMENT NUMBER: 149:519140
TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
INVENTOR(S): Braun, Marina; Schollmayer, Erwin; Sachse, Richard
PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 58pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008135527 | A2 | 20081113 | WO 2008-EP55413 | 20080502 |
| WO 2008135527 | A3 | 20090212 | | |

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1987815 A1 20081105 EP 2007-9013 20070504
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504
US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5 g/l, α-cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1324859 CAPLUS
DOCUMENT NUMBER: 149:500102
TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany
SOURCE: Eur. Pat. Appl., 33pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1987815 | A1 | 20081105 | EP 2007-9013 | 20070504 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

US 20080274061 A1 20081106 US 2008-114348 20080502
WO 2008135527 A2 20081113 WO 2008-EP55413 20080502
WO 2008135527 A3 20090212

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504
US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5 g/l, α-cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:284134 CAPLUS
DOCUMENT NUMBER: 142:349472
TITLE: As-needed administration of an androgenic agent to enhance female desire and responsiveness
INVENTOR(S): Wilson, Leland F.; Tam, Peter Y.
PATENT ASSIGNEE(S): Vivus Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 919,472.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20050070516 | A1 | 20050331 | US 2004-990667 | 20041116 |
| US 5877216 | A | 19990302 | US 1997-959064 | 19971028 |
| US 6306841 | B1 | 20011023 | US 2000-539484 | 20000330 |
| US 20020013304 | A1 | 20020131 | US 2001-919472 | 20010727 |

PRIORITY APPLN. INFO.:
US 1997-959057 B2 19971028
US 1997-959064 A2 19971028
US 1998-181316 B1 19981027
US 2000-539484 A2 20000330
US 2001-919472 A2 20010727

AB A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

IT 3605-01-4, Piribedil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. active agents; as-needed administration of an androgenic agent to enhance female desire and responsiveness)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:56829 CAPLUS
DOCUMENT NUMBER: 142:141273
TITLE: Pharmaceutical composition for the nasal administration of piribedil
INVENTOR(S): Rolland, Herve; Wuthrich, Patrick
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.; Servier Lab
SOURCE: Fr. Demande, 9 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| FR 2857594 | A1 | 20050121 | FR 2003-8712 | 20030717 |
| FR 2857594 | B1 | 20050916 | | |
| AU 2004258714 | A1 | 20050203 | AU 2004-258714 | 20040716 |
| CA 2532631 | A1 | 20050203 | CA 2004-2532631 | 20040716 |
| WO 2005009442 | A1 | 20050203 | WO 2004-FR1867 | 20040716 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| EP 1653963 | A1 | 20060510 | EP 2004-767691 | 20040716 |
| EP 1653963 | B1 | 20061227 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

| | | | | |
|---|---|---|---|---|
| CN 1819828 | A | 20060816 | CN 2004-80019749 | 20040716 |
| BR 2004012681 | A | 20061003 | BR 2004-12681 | 20040716 |
| AT 349213 | T | 20070115 | AT 2004-767691 | 20040716 |
| JP 2007516947 | T | 20070628 | JP 2006-519966 | 20040716 |
| ES 2279435 | T3 | 20070816 | ES 2004-767691 | 20040716 |
| NZ 544460 | A | 20080430 | NZ 2004-544460 | 20040716 |
| IN 2006DN00118 | A | 20070824 | IN 2006-DN118 | 20060106 |
| US 20060204449 | A1 | 20060914 | US 2006-564139 | 20060110 |
| MX 2006000641 | A | 20060330 | MX 2006-641 | 20060117 |
| KR 2006031689 | A | 20060412 | KR 2006-701141 | 20060117 |
| KR 807480 | B1 | 20080225 | | |
| NO 2006000743 | A | 20060216 | NO 2006-743 | 20060216 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | FR 2003-8712 | A | 20030717 |
| | WO 2004-FR1867 | W | 20040716 |

AB The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin) 750, and NaCl 68 mg, and water qs to 10 mL.

IT 3605-01-4, Piribedil
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for nasal administration of piribedil)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 1997:500259 CAPLUS |
| DOCUMENT NUMBER: | 127:113363 |
| ORIGINAL REFERENCE NO.: | 127:21773a,21776a |
| TITLE: | Controlled-release bioadhesive pharmaceutical compositions containing vinyl acetate-vinylpyrrolidone copolymer |
| INVENTOR(S): | Rault, Isabelle; Pichon, Gerald |
| PATENT ASSIGNEE(S): | Adir Et Compagnie, Fr. |
| SOURCE: | Eur. Pat. Appl., 7 pp. |

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 781550 | A1 | 19970702 | EP 1996-402788 | 19961218 |
| EP 781550 | B1 | 19961218 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| FR 2742989 | A1 | 19970704 | FR 1995-15701 | 19951229 |
| FR 2742989 | B1 | 19980123 | | |
| AT 222098 | T | 20020815 | AT 1996-402788 | 19961218 |
| PT 781550 | T | 20021129 | PT 1996-402788 | 19961218 |
| ES 2180722 | T3 | 20030216 | ES 1996-402788 | 19961218 |
| CA 2193454 | A1 | 19970630 | CA 1996-2193454 | 19961219 |
| CA 2193454 | C | 20010724 | | |
| NO 9605475 | A | 19970630 | NO 1996-5475 | 19961219 |
| ZA 9610864 | A | 19970627 | ZA 1996-10864 | 19961223 |
| AU 9675496 | A | 19970703 | AU 1996-75496 | 19961223 |
| AU 725283 | B2 | 20001012 | | |
| JP 09194395 | A | 19970729 | JP 1996-343671 | 19961224 |
| CN 1159950 | A | 19970924 | CN 1996-123198 | 19961227 |
| US 5900247 | A | 19990504 | US 1996-777306 | 19961227 |

PRIORITY APPLN. INFO.: FR 1995-15701 A 19951229

AB Bioadhesive pharmaceutical composition for the controlled release of active agents in buccal cavity or through nasal, vaginal, and rectal mucosa are claimed. The bioadhesive compns. contain vinyl acetate-vinylpyrrolidone copolymer (I) and polysaccharides. Dihydroergotamine monomethanesulfonate 0.15, I 5, and ethanol:0.1N HCl (50:50) 10 mL were mixed to obtain a homogeneous solution followed by addition of 0.5 g propylene glycol. The mixture thus obtained was spread on an ethylene-vinyl acetate film and dried at room temperature for 2h. Disks of 1 cm diameter having thickness of 0.2 mm were cut from above film for use.

IT 52293-23-9, Piribedil monomethane sulfonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release bioadhesive pharmaceutical compns. containing vinyl acetate-vinylpyrrolidone copolymer)

RN 52293-23-9 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 3605-01-4
CMF C16 H18 N4 O2




CM 2

CRN 75-75-2
CMF C H4 O3 S



L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:881856 CAPLUS
DOCUMENT NUMBER: 123:329760
ORIGINAL REFERENCE NO.: 123:58869a,58872a
TITLE: Different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry
AUTHOR(S): Jardon, Blandine; Bonaventure, Nicole
CORPORATE SOURCE: Laboratoire de Neurophysiologie et Biologie des Comportements, CNRS, Strasbourg, 67084, Fr.
SOURCE: Vision Research (1995), 35(19), 2665-73
CODEN: VISRAM; ISSN: 0042-6989
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Frog monocular optokinetic nystagmus (OKN) displays a directional asymmetry, reacting only to stimulations in the temporal-nasal (T-N) direction. The nasal-temporal (N-T) component is almost absent. The systemic or intrapretectal injection of Piribedil, a D2 dopamine agonist, provokes the appearance of a N-T component suppressing the monocular OKN asymmetry. Conversely, dopamine or haloperidol (a dopamine antagonist, acting mainly on D2 receptors) have no effect upon the monocular OKN unidirectionality. The monocular OKN N-T component still appears after administration of Piribedil even if this injection is preceded by administration of haloperidol which blocks the dopaminergic D2 receptors. Moreover administration of atropine (a cholinergic muscarinic antagonist) following that of Piribedil suppresses the N-T component; when injected before Piribedil, atropine prevents the appearance of the N-T component. These results suggest that in the expts., Piribedil binds with muscarinic receptors.

IT 3605-01-4, Piribedil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry)

RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



=> s l3 and mucousal
482 L3
5 MUCOUSAL

```
L6            0 L3 AND MUCOUSAL

=> s l3 and mucous
            482 L3
          16322 MUCOUS
              1 MUCOUSES
          16322 MUCOUS
                  (MUCOUS OR MUCOUSES)
L7            0 L3 AND MUCOUS

=> s l3 adn mucosal
MISSING OPERATOR L3 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l3 and mucosal
            482 L3
          45501 MUCOSAL
              5 MUCOSALS
          45503 MUCOSAL
                  (MUCOSAL OR MUCOSALS)
L8            2 L3 AND MUCOSAL

=> d ibib abs hitstr 1-2

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:233290  CAPLUS
DOCUMENT NUMBER:          150:252678
TITLE:                    Combinations containing MPO inhibitors against
                          neuroinflammatory disorders
INVENTOR(S):              Aahlberg, Gabrielle; Eriksson, Haakan
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 41pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2009025617         A1    20090226    WO 2008-SE50949         20080822
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     US 20090053176        A1    20090226    US 2008-195505          20080821
PRIORITY APPLN. INFO.:                       US 2007-957524P     P   20070823
AB   The present invention related to a combination of (a) a compound which is a
     MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a
     compound or a pharmaceutically acceptable salt thereof, which is used in the
     treatment and/or prevention of PD or Multiple Sclerosis.  The invention
     further relates to pharmaceutical compns. comprising said combination and
     to methods of treating Neuroinflammatory and Neurodegenerative
```

Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).

IT 3605-01-4, Piribedil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations containing MPO inhibitors against neuroinflammatory disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1088890 CAPLUS

DOCUMENT NUMBER: 147:392440

TITLE: Transdermal delivery of systemically active central nervous system drugs

INVENTOR(S): Carrara, Dario Norberto R.; Grenier, Arnaud; Alberti, Igno; Henry, Laetitia; Decaudin, Celine

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 634,005.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070225379 | A1 | 20070927 | US 2007-755923 | 20070531 |
| WO 2002011768 | A1 | 20020214 | WO 2001-EP9007 | 20010803 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20030199426 | A1 | 20031023 | US 2003-343570 | 20030519 |
| US 7214381 | B2 | 20070508 | | |
| AU 2004283431 | A1 | 20050506 | AU 2004-283431 | 20041006 |
| CA 2538856 | A1 | 20050506 | CA 2004-2538856 | 20041006 |
| WO 2005039531 | A1 | 20050506 | WO 2004-EP11175 | 20041006 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, | | | | |

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| EP 1670433 | A1 | 20060621 | EP 2004-790156 | | 20041006 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| BR 2004014551 | A | 20061031 | BR 2004-14551 | | 20041006 |
| JP 2007508261 | T | 20070405 | JP 2006-530107 | | 20041006 |
| NZ 546106 | A | 20081031 | NZ 2004-546106 | | 20041006 |
| US 20060153905 | A1 | 20060713 | US 2006-371042 | | 20060307 |
| US 7335379 | B2 | 20080226 | | | |
| MX 2006003316 | A | 20060608 | MX 2006-3316 | | 20060324 |
| US 20070098775 | A1 | 20070503 | US 2006-634005 | | 20061204 |
| US 7404965 | B2 | 20080729 | | | |
| US 20090069364 | A1 | 20090312 | US 2008-268301 | | 20081110 |
| PRIORITY APPLN. INFO.: | | | WO 2001-EP9007 | W | 20010803 |
| | | | US 2003-343570 | A1 | 20030519 |
| | | | US 2003-510613P | P | 20031010 |
| | | | WO 2004-EP11175 | A1 | 20041006 |
| | | | US 2006-371042 | A2 | 20060307 |
| | | | US 2006-634005 | A2 | 20061204 |
| | | | WO 2000-EP7533 | A | 20000803 |
| | | | US 2007-755923 | A2 | 20070531 |

AB The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the central nervous system (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient. The permeation enhancing solvent system includes a pharmaceutically acceptable monoalkyl ether of diethylene glycol; a pharmaceutically acceptable glycol; preferably also a fatty alc. and or a fatty acid; and a mixture of a C2 to C4 alc. and water so that the permeation enhancing solvent system (a) inhibits crystallization of the at least one active ingredient on a skin or mucosal surface of a mammal, (b) reduces or prevents transfer of the formulation to clothing or to another being, (c) modulates biodistribution of the at least one active agent within different layers of skin, (d) facilitates absorption of the at least one active agent by a skin or a mucosal surface of a mammal, or (e) provides a combination of one or more of (a) through (d). A transdermal pharmaceutical contained pramipexole dihydrochloride 2.00, diethylene glycol monoethyl ether 5.00, propylene glycol 15.0, hydroxypropylcellulose 1.50, absolute ethanol 4.0, sodium hydroxide q.s. pH = 8.2, and water q.s. 100.00%.

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of systemically active central nervous system drugs)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



```
=> s l3 and mucosa
           482 L3
         67643 MUCOSA
           311 MUCOSAS
          1496 MUCOSAE
         68485 MUCOSA
                 (MUCOSA OR MUCOSAS OR MUCOSAE)
L9           1 L3 AND MUCOSA

=> d ibib abs hitstr 1

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         1997:500259  CAPLUS
DOCUMENT NUMBER:          127:113363
ORIGINAL REFERENCE NO.:   127:21773a,21776a
TITLE:                    Controlled-release bioadhesive pharmaceutical
                          compositions containing vinyl acetate-vinylpyrrolidone
                          copolymer
INVENTOR(S):              Rault, Isabelle; Pichon, Gerald
PATENT ASSIGNEE(S):       Adir Et Compagnie, Fr.
SOURCE:                   Eur. Pat. Appl., 7 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     EP 781550            A1    19970702    EP 1996-402788         19961218
     EP 781550            B1    19961218
         R:  AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     FR 2742989           A1    19970704    FR 1995-15701          19951229
     FR 2742989           B1    19980123
     AT 222098            T     20020815    AT 1996-402788         19961218
     PT 781550            T     20021129    PT 1996-402788         19961218
     ES 2180722           T3    20030216    ES 1996-402788         19961218
     CA 2193454           A1    19970630    CA 1996-2193454        19961219
     CA 2193454           C     20010724
     NO 9605475           A     19970630    NO 1996-5475           19961219
     ZA 9610864           A     19970627    ZA 1996-10864          19961223
     AU 9675496           A     19970703    AU 1996-75496          19961223
     AU 725283            B2    20001012
     JP 09194395          A     19970729    JP 1996-343671         19961224
     CN 1159950           A     19970924    CN 1996-123198         19961227
     US 5900247           A     19990504    US 1996-777306         19961227
PRIORITY APPLN. INFO.:                      FR 1995-15701       A  19951229
AB   Bioadhesive pharmaceutical composition for the controlled release of active
     agents in buccal cavity or through nasal, vaginal, and rectal
     mucosa are claimed.  The bioadhesive compns. contain vinyl
     acetate-vinylpyrrolidone copolymer (I) and polysaccharides.
     Dihydroergotamine monomethanesulfonate 0.15, I 5, and ethanol:0.1N HCl
     (50:50) 10 mL were mixed to obtain a homogeneous solution followed by addition
     of 0.5 g propylene glycol.  The mixture thus obtained was spread on an
     ethylene-vinyl acetate film and dried at room temperature for 2h.  Disks of 1
cm
     diameter having thickness of 0.2 mm were cut from above film for use.
IT   52293-23-9, Piribedil monomethane sulfonate
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
```

(controlled-release bioadhesive pharmaceutical compns. containing vinyl acetate-vinylpyrrolidone copolymer)

RN 52293-23-9 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 3605-01-4
CMF C16 H18 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 85.70 | 271.80 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -9.02 | -9.02 |

STN INTERNATIONAL LOGOFF AT 13:06:29 ON 06 APR 2009